≪英文≫

Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma.

Tanaka A, Yano I, Shinsako K, Sato E, Fukudo M, Masuda S, Yamasaki T, Kamba T, Ogawa O, Matsubara K.

Ther Drug Monit. 2016 Dec;38(6):663-669.

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.

Arakaki R, Yamasaki T, Kanno T, Shibasaki N, Sakamoto H, Utsunomiya N, Sumiyoshi T, Shibuya S, Tsuruyama T, Nakamura E, Ogawa O, Kamba T.

Cancer Med. 2016 Oct;5(10):2920-2933.

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S.

Cancer Sci. 2016 Jul;107(7):1013-7.

Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma.

Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T,Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M.

Cancer Sci. 2016 May;107(5):700-7.

Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.

Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Theeuwes A, Beer TM, Tombal B, Ueda T.

Int J Urol. 2016 May;23(5):395-403.

CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma.

Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M.

Oncol Lett. 2016 Mar;11(3):1911-1916.